31
edits
Changes
Jump to navigation
Jump to search
Line 20:
Line 20: − | AML including NK-AML − | CN-LOH − | 1p − + − + + + + − | 2 − | AML − | CN-LOH − | 2p − | ''DNMT3A'' − | D − | 3 − |- − | 3 − | NK-AML, sAML − | Loss − | 3p14.1 − | ''FOXP1'' − | D − | 3 − |- − | 4 − | sAML, pAML − | CN-LOH − | 4q24 − | ''TET2'' − | D − | 3 − |- − | 4 − | AML, NK-AML, sAML − | Loss − | 4q24 − | ''TET2'' − | D, P − | 3 − |- − | 5 − | pAML, sAML − | Loss − | 5q − | − | D − | 1 − |- − | 6 − | AML including NK-AML − | CN-LOH − | 6p − | − | D − | 3 − |- − | 7 − | AML including NK-AML − | CN-LOH − | 7q − | ''EZH2'' − | D − | 3 − |- − | 7 − | NK-AML, pAML, sAML − | Loss − | 7q − | ''EZH2, CUX1'' − | D − | 1 − |- − | 8 − | AML with complex karyotype − | Amplification − | 8q24 − | ''MYC'' − | D, P − | 3 − |- − | 9 − | NK-AML, sAML − | CN-LOH − | 9p − | ''JAK2'' − | D − | 3 − |- − | 11* − | AML with complex karyotype − | Amplification − | 11q23 − | ''MLL (KMT2A)'' − | D, P − | 3 − |- − | 11* − | AML − | CN-LOH − | 11p − | ''WT1'' − | D − | 3 − |- − | 11 − | pAML, sAML, NK-AML − | CN-LOH − | 11q − | ''CBL'' − | D − | 3 − |- − | 12 − | AML, NK-AML, AML with complex karyotype, sAML − | Loss − | 12p13.2 − | ''ETV6'' − | D − | 3 − |- − | 13* − | pAML, NK-AML, ''NPM1'' mutated AML, FLT3-ITD positive AML, sAML − | CN-LOH − | 13q − | ''FLT3'' − | D, P − | 2 − |- − | 16 − | NK-AML, AML with complex karyotype, pAML, sAML − | Loss − | 16q − | ''CBFB'' − | D − | 3 − |- − | 17 − | AML, NK-AML, pAML, sAML − | CN-LOH − | 17p − | ''TP53'' − | D − | 3 − |- − | 17 − | sAML, NK-AML, AML with complex karyotype, ''de novo'' AML − | Loss − | 17p − | ''TP53'' − | D, P − | 1 − |- − | 17 − | NK-AML, pAML − | Loss − | 17q11.2 − | ''NF1, SUZ12'' − | D, P − | 3 − |- − | 19* − | AML, NK-AML, sAML − | CN-LOH − | 19q − | ''CEBPA'' − | D − | 3 − |- − | 20 − | sAML − | Loss − | 20q − | − | D − | 3 − |- − | 21* − | pAML, AML with complex karyotype − | Amplification − | 21q22 − | ''ERG, ETS2'' − | D, P, T − | 3 − |- − | 21* − | AML, NK-AML, sAML − | CN-LOH − | 21q − | ''RUNX1'' − | D − | 3 − |- − | 21* − | sAML − | Loss − | 21q22.12 − | ''RUNX1'' − | D − | 3 − |- − |} − D = diagnostic significance; P = prognostic significance; T = therapeutic significance. Classification of levels of evidence: Level 1 = WHO classification or professional practice guidelines; Level 2 = well-powered studies with consensus from experts in the field; Level 3 = multiple small studies without any contradicting data; Level 4 = individual small studies, case reports, preclinical studies. − − Abrreviations: CMA = chromosomal microarray; CNA = copy number aberration; CN-LOH = copy-neutral loss-of-heterozygosity; AML = acute myeloid leukemia; NK-AML = normal karyotype AML; pAML = primary AML; and sAML = secondary AML. − − The * indicates CNAs and CN-LOH regions that are predominantly seen in AML. − − ==Reference== − − 1. Xu X, Bryke C, Sukhanova M, Huxley E, Dash DP, Dixon-Mciver A, Fang M, Griepp PT, Hodge JC, Iqbal A, Jeffries S, Kanagal-Shamanna R, Quintero-Rivera F, Shetty S, Slovak ML, Yenamandra A, Lennon PA, Raca G. (2018). Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. Cancer Genet [Epub ahead of print], PMID 30344013.
Recurrent Genomic Alterations in Pediatric and Adult Central Nervous System Tumors Detected by Chromosomal Microarray (view source)
Revision as of 13:02, 15 November 2018
, 13:02, 15 November 2018no edit summary
| PMID:19016743; PMCID:2761618; PMID:18716556 PMID:25461780 PMID:25664944; PMID:26378811 PMCID:3429698; PMID:23817572; PMID:23583981 PMID:18974108; PMID:23278243; PMID:21274720
| PMID:19016743; PMCID:2761618; PMID:18716556 PMID:25461780 PMID:25664944; PMID:26378811 PMCID:3429698; PMID:23817572; PMID:23583981 PMID:18974108; PMID:23278243; PMID:21274720
|-
|-
|
|
| D
| Angiocentric glioma
| 3
| Aberrations involving 6q24-q25
| '''Fusions:''' MYB-QKI rearrangement/deletion (classic histology); '''Rearrangement:''' MYB alone (atypical histology); '''Amplification:''' MYB (atypical histology)
| Generally indolent tumors; surgical resection can be curative
| PMID:26829751; PMID:23633565; PMID:26778052 PMID:23583981
|-
|-